QQQ   420.10 (+1.31%)
AAPL   166.69 (+1.02%)
MSFT   401.73 (+0.65%)
META   485.37 (+0.89%)
GOOGL   156.95 (+1.86%)
AMZN   177.57 (+1.68%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.22 (+1.76%)
NIO   4.02 (+5.79%)
BABA   70.82 (+2.53%)
T   16.35 (-0.97%)
F   12.87 (+6.01%)
MU   109.79 (+2.83%)
GE   150.78 (+1.84%)
CGC   7.90 (-0.38%)
DIS   112.80 (+0.17%)
AMC   3.40 (+7.59%)
PFE   26.41 (+1.58%)
PYPL   63.29 (+1.57%)
XOM   121.16 (+1.07%)
QQQ   420.10 (+1.31%)
AAPL   166.69 (+1.02%)
MSFT   401.73 (+0.65%)
META   485.37 (+0.89%)
GOOGL   156.95 (+1.86%)
AMZN   177.57 (+1.68%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.22 (+1.76%)
NIO   4.02 (+5.79%)
BABA   70.82 (+2.53%)
T   16.35 (-0.97%)
F   12.87 (+6.01%)
MU   109.79 (+2.83%)
GE   150.78 (+1.84%)
CGC   7.90 (-0.38%)
DIS   112.80 (+0.17%)
AMC   3.40 (+7.59%)
PFE   26.41 (+1.58%)
PYPL   63.29 (+1.57%)
XOM   121.16 (+1.07%)
QQQ   420.10 (+1.31%)
AAPL   166.69 (+1.02%)
MSFT   401.73 (+0.65%)
META   485.37 (+0.89%)
GOOGL   156.95 (+1.86%)
AMZN   177.57 (+1.68%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.22 (+1.76%)
NIO   4.02 (+5.79%)
BABA   70.82 (+2.53%)
T   16.35 (-0.97%)
F   12.87 (+6.01%)
MU   109.79 (+2.83%)
GE   150.78 (+1.84%)
CGC   7.90 (-0.38%)
DIS   112.80 (+0.17%)
AMC   3.40 (+7.59%)
PFE   26.41 (+1.58%)
PYPL   63.29 (+1.57%)
XOM   121.16 (+1.07%)
QQQ   420.10 (+1.31%)
AAPL   166.69 (+1.02%)
MSFT   401.73 (+0.65%)
META   485.37 (+0.89%)
GOOGL   156.95 (+1.86%)
AMZN   177.57 (+1.68%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.22 (+1.76%)
NIO   4.02 (+5.79%)
BABA   70.82 (+2.53%)
T   16.35 (-0.97%)
F   12.87 (+6.01%)
MU   109.79 (+2.83%)
GE   150.78 (+1.84%)
CGC   7.90 (-0.38%)
DIS   112.80 (+0.17%)
AMC   3.40 (+7.59%)
PFE   26.41 (+1.58%)
PYPL   63.29 (+1.57%)
XOM   121.16 (+1.07%)
NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

$30.50
+0.97 (+3.28%)
(As of 03:03 PM ET)
Today's Range
$29.50
$30.89
50-Day Range
$25.15
$34.81
52-Week Range
$19.80
$35.50
Volume
541,307 shs
Average Volume
801,616 shs
Market Capitalization
$1.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.50

Agios Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.8% Upside
$33.50 Price Target
Short Interest
Bearish
12.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$950,297 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.11) to ($5.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.30 out of 5 stars

Medical Sector

508th out of 907 stocks

Pharmaceutical Preparations Industry

232nd out of 428 stocks

AGIO stock logo

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Stock Price History

AGIO Stock News Headlines

The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
AGIO Apr 2024 40.000 call
AGIO Apr 2024 25.000 put
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Agios Pharmaceuticals Inc AGIO
Q4 2023 Agios Pharmaceuticals Inc Earnings Call
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/22/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
383
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.50
High Stock Price Target
$42.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-352,090,000.00
Net Margins
-1,312.64%
Pretax Margin
-1,312.64%

Debt

Sales & Book Value

Annual Sales
$26.82 million
Book Value
$14.51 per share

Miscellaneous

Free Float
53,812,000
Market Cap
$1.66 billion
Optionable
Optionable
Beta
0.83
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Brian M. Goff M.B.A. (Age 55)
    CEO & Director
    Comp: $1.23M
  • Ms. Cecilia Jones (Age 49)
    Chief Financial Officer
    Comp: $403.36k
  • Mr. James William Burns (Age 46)
    Corporate Secretary & Chief Legal Officer
    Comp: $660.33k
  • Dr. Sarah Gheuens M.D. (Age 43)
    Ph.D., Chief Medical Officer and Head of Research & Development
    Comp: $769.2k
  • Dr. Lewis Clayton Cantley Ph.D. (Age 75)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $50k
  • Dr. Tak Wah Mak D.Sc. (Age 78)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 71)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 68)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. T. J. Washburn Jr. (Age 43)
    Principal Accounting Officer
  • Dr. Clive Patience Ph.D. (Age 60)
    Chief Technical Operations Officer

AGIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price target for 2024?

4 brokerages have issued twelve-month target prices for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $42.00. On average, they predict the company's share price to reach $33.50 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2024?

Agios Pharmaceuticals' stock was trading at $22.27 at the beginning of the year. Since then, AGIO stock has increased by 37.0% and is now trading at $30.50.
View the best growth stocks for 2024 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AGIO earnings forecast
.

How can I listen to Agios Pharmaceuticals' earnings call?

Agios Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing analysts' consensus estimates of ($1.64) by $0.08. The biopharmaceutical company earned $7.10 million during the quarter, compared to analysts' expectations of $7.80 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative trailing twelve-month return on equity of 38.08%. Agios Pharmaceuticals's revenue for the quarter was up 65.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.67 earnings per share.

What ETFs hold Agios Pharmaceuticals' stock?
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGIO) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners